Q2 2018 13F Holders as of 30 Jun 2018
-
Type / Class
-
Equity / Common Shares, no par value
-
Shares outstanding
-
131M
-
Number of holders
-
65
-
Total 13F shares, excl. options
-
21.3M
-
Shares change
-
-436K
-
Total reported value, excl. options
-
$122M
-
Value change
-
-$2.41M
-
Put/Call ratio
-
4.2
-
Number of buys
-
27
-
Number of sells
-
-22
-
Price
-
$5.63
Significant Holders of Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) as of Q2 2018
77 filings reported holding AUPH - Aurinia Pharmaceuticals Inc. - Common Shares, no par value as of Q2 2018.
Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) has 65 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 21.3M shares
of 131M outstanding shares and own 16.28% of the company stock.
Largest 10 shareholders include NEA Management Company, LLC (4.81M shares), FMR LLC (4.59M shares), Polar Capital LLP (2.6M shares), GOLDMAN SACHS GROUP INC (1.83M shares), FRANKLIN RESOURCES INC (1.73M shares), Vivo Capital, LLC (1.21M shares), BlackRock Inc. (980K shares), Abingworth LLP (400K shares), AMERIPRISE FINANCIAL INC (300K shares), and Hudson Bay Capital Management LP (230K shares).
This table shows the top 65 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.